Well I guess there were not many folks
who listened in...I was going to listen again
and tidy up my notes before posting them, but
hell, why bother. I was about the only one to
buy shares today, it is so lonely.
If anybody else is going to listen, the magn
talk is about 3/5ths into that tape, took me
a good five minutes to locate it, but at least
it was good and clear. You might print out my
notes, and use them as a first draft...lots of
holes, but I got the high points I think. There
were two times when Zasloff said just strait out
that he expects approval, very bold.
Notes on Magainin from the Vcall session:
Chief Science Officer, Zasloff
Extremely low probability that bacteria will
develop a resistance to the Magainin antibotic
peptide. We chose the diabetic ulcer because
it is a particularly difficult problem. This
drug completed two phase III trials involving
1000 patients. Comperable results for topical
locilex were found with no side effects.
Advisory panel
FDA has to give an answer by July 24th
Three scenarios
1. Another study involving placebo
2. Approve, and continue to work
3. Drop the matter entirely
14m w/ diabetes, 700,000 with ulcers
2 1/2M total, bed sores, other lesions
40k/year to treat diabetic foot ulcers
S.C.B. has introduced another drug, and these
two drugs will be marketed together etc etc
and scb is working on the assumption that loc.
will be approved.
MAGN will receive 40% of sales
Broadest spectrum of any antibiotic
NO irritation
Can be used for extended periods of time
Squalamine:
masks the effect of growth factor
How to best use squal. (slide)
Taxol+Carboplatin, tumor grows back,
"+Squal, just for a few days, there is
a profound result....
Squal. is...
lung...
breast...
Phase I about to be completed, have everything
we need to go to phase II, which begins in a couple
weeks--efficacy, metastatic lung cancer.
Asthma:
We brought this program into the company two years
ago, Levitt came oer from Hopkins, NIH, ten years
of work, IL9, unrecognized player in asthma, now there
are three areas to the program.
IL9<<collaborative agreement with GNE
Steroids supress everything like a hammer
supress just IL9, and you would effect things
at an earlier stage. IL9 antibody supresses
the asthma wheezeing, GNE put 2M of 35M agreement
with magn, excited about generating the antibodies
for IL9.
Much of the MAGN astma program remains Magainin's,
those shark compounds. Functional disruption, there
are a number of companies that are interested in this,
...interested in this general area.
__
Expression of antibotics: Stimulate these systems to
produce greater amounts of antibotics...
19M cash
20M shares
burn reduced by half
profoundly undervalued
market potential of loc....it will be marketd
125M/year for just the indicated use
25% for Magn for profit.
Not yet decided who they will partner loc internatinally
Squal. and Asthma not yet valued.
Questions:
10-15% of the time fda approves
there was no problem with the design of the trials
FDA originally refused placebo
FDA called magn the day after...and said continue
your development, dialog has continued on what to
do pre and post approval.
European market: Many possibilities, a number of
groups in Europ. market who would like to see this
marketed under their name.
GNE humanized antibody, mouse antibody...create the
best possible reagent and see if blockade of IL9
really does produce the benefit--creating the
therapeutic--an antibody which works perfectly in
the mouse, and the human part
MAGN is commited to stay lean and cash balanced |
